Inventiva S.A.
Clinical-stage biopharma developing oral therapies for fibrosis and metabolic disorders.
IVA | US
Overview
Corporate Details
- ISIN(s):
- US46124U1079
- LEI:
- Country:
- United States of America
- Address:
- 50 RUE DE DIJON, 21121 DAIX
- Website:
- https://inventivapharma.com/
- Sector:
- Manufacturing
Description
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies that target nuclear receptors and transcription factors. The company's primary focus is on diseases with significant unmet medical needs, including fibrosis and metabolic disorders. Its lead product candidate, lanifibranor, is a pan-PPAR agonist in development for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including inflammation, steatosis, ballooning, and fibrosis. Following positive Phase IIb results, the U.S. Food and Drug Administration (FDA) granted lanifibranor Breakthrough Therapy Designation. The candidate is currently being evaluated in a pivotal Phase III clinical trial (NATiV3).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inventiva S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Inventiva S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inventiva S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
